Where You Live Shapes How Badly Iran Impacts Your Finances
Regional disparities in the Iran conflict determine how households budget for energy, groceries, and bills. A new Oxf...
Articles — Page 1184
Intelligence Scalable, Accountability Not: AI Costs Rising
A joint Accenture-Wharton study finds AI agents can scale thinking, but human governance struggles to keep pace, crea...
Biggest Investing Mistakes CFP® and How to Avoid Them
As a CFP®, I see recurring investing mistakes that erode gains. This practical guide shows how to spot them and turn ...
NVIDIA's Networking Revenue Just Reshapes AI Investing
AI is advancing beyond chips. NVIDIA's networking revenue just signals a broader shift to end-to-end AI infrastructur...
Reasons IBM's COBOL Fears: Why They're Overblown Today
Two big reasons explain why the fear around IBM's COBOL future might be overstated. This piece breaks down why COBOL ...
Rockwell Medical (RMTI) Earnings: Key Takeaways for 2026
Rockwell Medical is a niche player in renal care. This analysis breaks down rockwell medical (rmti) earnings, what th...
Best Places to Retire: Smart Choices for Your Golden Years
Choosing where to retire isn’t just about weather. It blends cost, healthcare access, taxes, and lifestyle. This guid...
Retirees: Artificial Intelligence (AI) Stock Guide for 2026
If you’re a retiree with AI stock exposure, you’re not alone. This guide explains how to protect income, rebalance ri...
Everybody Thinks Spending Peaking? Look at the AI Orders
The market mood says AI spending is peaking. But one company’s long-term orders hint at a different story. This guide...
FSTA FTXG: Which Consumer Staples ETF Is the Better Buy?
Two popular consumer staples ETFs—FSTA and FTXG—offer different routes to defense in a volatile market. This guide br...
Emerging Markets ETFs Boasts Higher Returns and Lower Fees
If you’re building a global portfolio, two popular options to consider are SCHE and EEM. This guide explains how emer...
Lucid Diagnostics (LUCD) Earnings: Outlook and Analysis
Lucid Diagnostics (LUCD) is navigating reimbursement and adoption as it scales its non-invasive tests. This analysis ...